临床阶段生物技术公司Synhale Therapeutics宣布收购一流的谷氨酰胺酶抑制剂Telaglenastat，加速肺动脉高压治疗的开发-动脉网

Synhale Therapeutics Acquires Telaglenastat, Accelerates Development for Pulmonary Hypertension Treatment

CISION 等信源发布 2025-05-02 02:51



可切换为仅中文







PITTSBURGH

匹兹堡

and

和

BOSTON

波士顿

，

May 1, 2025

2025年5月1日

/PRNewswire/ -- Synhale Therapeutics Inc. (Synhale), a virtual, clinical-stage biotech company committed to transforming Pulmonary Hypertension (PH), announced the acquisition of Telaglenastat (CB-839), the first-in-class glutaminase inhibitor. Synhale is advancing into a Phase 2 clinical program across PH Groups 1-4..

/PRNewswire/ -- Synhale Therapeutics Inc.（Synhale），一家致力于变革肺动脉高压（PH）的虚拟临床阶段生物技术公司，宣布收购了首创的谷氨酰胺酶抑制剂Telaglenastat（CB-839）。Synhale正在推进针对PH第1至4组的二期临床计划。

'This acquisition represents a unique opportunity to rapidly deliver clinical data addressing a disease with high mortality and substantial market potential,' said

“此次收购代表了一个独特的机会，可以迅速提供针对一种高死亡率和巨大市场潜力的疾病的临床数据，”

Chad D. Holland

查德·D·霍兰德

, President & CEO of Synhale. 'Leveraging Telaglenastat's prior human clinical experience, our capital-efficient model aims to accelerate transformative therapy to patients while maximizing shareholder value.'

Synhale公司总裁兼首席执行官表示：“利用Telaglenastat先前的人体临床经验，我们资本高效的模式旨在加速将变革性疗法带给患者，同时最大化股东价值。”

Stephen Chan

陈史蒂芬

, MD, PhD, Founder of Synhale, added, 'The unmet patient need in PH is immense, particularly in Groups 2 and 3, where heart failure with preserved ejection fraction (HFpEF) and chronic lung disease remain deadly and underserved. PH with HFpEF carriers a five-year mortality approaching 50%, with similarly grim outcomes in COPD and other lung diseases.

医学博士、Synhale创始人补充道：“PH（肺动脉高压）中未满足的患者需求是巨大的，尤其是在第2组和第3组，心力衰竭伴保留射血分数（HFpEF）和慢性肺病仍然是致命且服务不足的问题。伴有HFpEF的PH其五年死亡率接近50%，在COPD和其他肺疾病中的结果同样严峻。”

By targeting glutaminase activity, we address a fundamental metabolic pathway across all PH groups, offering hope to patients with few options.'.

通过针对谷氨酰胺酶活性，我们解决了一个贯穿所有PH组群的基本代谢途径，为选择很少的患者带来了希望。

PH, a severe condition, is characterized by remodeling and stiffening in the pulmonary vasculature and often dramatically increases mortality risk when combined with other conditions. Current classifications fail to reflect the molecular drivers of PH, leaving treatment gaps. Synhale's approach with Telaglenastat targets elevated glutaminase activity, a key driver of vascular, cardiac, and pulmonary pathology, potentially benefiting not only rare Pulmonary Arterial Hypertension (Group 1) and chronic thromboembolic disease (Group 4) but also more prevalent PH linked to heart failure (Group 2) and chronic lung disease (Group 3)..

肺动脉高压 (PH) 是一种严重的疾病，其特征是肺血管的重塑和僵硬，当与其他疾病并存时往往会显著增加死亡风险。目前的分类未能反映 PH 的分子驱动因素，导致治疗上的空白。Synhale 使用 Telaglenastat 的方法针对谷氨酰胺酶活性升高这一关键驱动因素，谷氨酰胺酶活性升高是血管、心脏和肺部病理的关键驱动因素，不仅可能使罕见的肺动脉高压（第 1 组）和慢性血栓栓塞性疾病（第 4 组）患者受益，还可能帮助更常见的与心力衰竭（第 2 组）和慢性肺病（第 3 组）相关的 PH 患者。

Telaglenastat, previously dosed in over 800 patients during oncology development, is Phase 2-ready with extensive preclinical data for PH. Synhale's clinical advancement strategy addresses an estimated

Telaglenastat曾在肿瘤学开发期间对超过800名患者进行过剂量测试，现已准备进入第二阶段，并拥有针对PH的广泛临床前数据。Synhale的临床推进策略针对一个预估的

$12B

120亿美元

$24B

240亿美元

market opportunity across PH Groups 1-4.

PH 1-4组的市场机会。

'We are embarking on our next round of fundraising to advance Telaglenastat through critical clinical milestones,' added Holland. 'Our virtual operating model enables us to be capital-efficient while maintaining world-class expertise focused on delivering breakthrough therapies for PH patients.'

“我们即将开始下一轮融资，以推动Telaglenastat通过关键的临床里程碑，”Holland补充道。“我们的虚拟运营模式使我们能够实现资本高效，同时保持世界级的专业团队，专注于为PH患者提供突破性疗法。”

About Synhale Therapeutics

关于Synhale Therapeutics

Synhale Therapeutics Inc. is a virtual biotech company dedicated to transforming Pulmonary Hypertension treatment by targeting elevated glutaminase activity—a key driver of vascular stiffness, fibrosis, and proliferation. Synhale's mission is to redefine PH treatment through mechanism-driven therapies that address the root cause of this disease..

Synhale Therapeutics Inc. 是一家虚拟生物技术公司，致力于通过靶向升高的谷氨酰胺酶活性来改变肺动脉高压的治疗 —— 谷氨酰胺酶活性是血管硬化、纤维化和增殖的关键驱动因素。Synhale 的使命是通过针对该疾病根本原因的机制驱动疗法重新定义肺动脉高压治疗。

For Media & Investor Inquiries:

媒体和投资者咨询：

Chad D. Holland

查德·D·霍兰德

info@synhale.com

617-758-8643

SOURCE Synhale Therapeutics Inc.

来源：Synhale Therapeutics Inc.

WANT YOUR COMPANY'S NEWS

想要你公司的新闻

FEATURED ON PRNEWSWIRE.COM?